Aishat Magbade is a Project Manager at The Conafay Group with a background in public health policy, advocacy, and strategic partnerships.
Ms. Magbade’s passion for public health and health equity began while she earned her undergraduate degree in Community Health from the University of Maryland. While there, she used community-based research to study disparities in cancer treatment at the Community Health Awareness, Messages and Prevention (CHAMP) lab. She focused on how faith-based messaging can lead to increased screening of breast, prostate, and colorectal cancers in predominantly Black communities.
Ms. Magbade completed her practicum as an intern at the African American Health Program with the Montgomery County Department of Health and Human Services. During this time, she wrote curricula for maternal oral health and implanted an afterschool program focused on nutrition and physical exercise for children. Following her graduation, Ms. Magbade continued to gain health policy experience on a wide range of issues through internships at the Hepatitis Foundation International, the Blue Cross Blue Shield Association, and the Better Medicare Alliance.
Following her internships, Ms. Magbade worked at the American Society for Microbiology where she managed federal grants on biosecurity, laboratory capacity, and antimicrobial resistance around the globe. She then worked at the American Society of Clinical Oncology (ASCO) where she collaborated with 46 regional oncology societies to identify emerging issues affecting the practice of oncology and patient care. Ms. Magbade focused on finding avenues to strengthen ASCO’s relationships with the state oncology societies and supported the societies’ association management system.
Prior to joining The Conafay Group, Ms. Magbade worked at the Alliance for Regenerative Medicine, where she managed committees focused on government relations and market access in the United States and Europe. Ms. Magbade also found opportunities to foster member engagement and form strategic partnerships with therapeutic developers, patient advocacy organizations, and other stakeholders to advance the cell and gene therapy sector and bring life changing therapies to those in need.